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ABSTRACT 
Dynamin and Cathepsin L: Biomarkers of Proteinuric Kidney Disease? 
Background 
Chronic kidney disease (CKD) is a major public health problem. It is important to be able to 
identify those individuals at high risk of CKD progression in order to implement strategies to 
delay progression to end stage renal disease. Hence, early more sensitive biomarkers are 
required. Recently, promising new biomarkers have been identified for monitoring CKD 
progression. 
Objectives 
 To determine whether Dynamin and Cathepsin L can be used as biomarkers for 
proteinuric chronic kidney disease (CKD).  
 To compare the levels of Dynamin and Cathepsin L in serum and urine of participants 
with proteinuric kidney disease to those of normal controls. 
 To determine if the levels of Cathepsin L and Dynamin correlates with the degree of 
proteinuria.  
Methods 
A prospective study of 37 patients with proteinuric kidney disease versus a healthy control 
group of 40 individuals, where the serum and urine levels of Cathepsin L and Dynamin were 
determined using an Enzyme Linked immunosorbent assay and the levels compared between 
the two groups.  
Data Analysis 
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The sample size was determined from previous similar studies, with assistance of a 
statistician. Sample size was calculated by comparing the means of the groups where the 
average value for sample 1= 1.0 (standard deviation=0.5); average value sample 2= 1.5 
(standard deviation=0.5; alpha= 5% and beta= 20%. A sample size of 20 was initially 
selected for the kidney disease group and 20 for the Control group (to give a 1:1 ratio). The 
numbers were there after doubled to increase sample size in order to improve the statistics.  
 An independent sample t-test was used to assess whether the mean serum Dynamin, urine 
Dynamin, serum Cathepsin L and urine Cathepsin L differed for the control group compared 
with kidney disease group. Pearson’s correlation analysis was used to measure the strength of 
the relationship between variables. Statistical significance was p<0.05.   
 
Results  
There was a significant increase in the level of urine Cathepsin L in the renal disease group 
10.44±11.47 pg/ml compared with the control group  2.91±2.88 pg/ml; p= 0.000. There was 
no difference in the levels of serum Cathepsin L between the renal disease and the control 
groups (p= 0.23). There were no significant differences in the levels of Dynamin in the serum 
and urine of patients with proteinuric renal disease and controls (p-values 0.11 and 0.13 
respectively).  
Although serum Cathepsin L (r = -0.22, p-value = 0.19), urine Cathepsin (r = -0.07, p-value = 
0.68), and urine Dynamin (r = -0.04, p-value = 0.83) are negatively related to the degree of 
proteinuria, the correlation is not significant; all the p-values were greater than 0.05. Serum 
Dynamin (r = 0.12, p-value = 0.49) had a positive correlation to the degree of proteinuria but 
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the correlation was not significant at the 5% significance level. Thus, there is no correlation 
between Cathepsin L and Dynamin levels with the degree of proteinuria. 
 
Discussion 
Podocyte dysfunction is a key element in understanding the progression of CKD resulting in 
proteinuria. In this study, levels of Cathepsin L and Dynamin were determined in participants 
with proteinuric renal disease and compared with healthy controls. Cathepsin L levels were 
elevated in the urine of the renal disease group, in keeping with the notion  that Cathepsin L 
proteolysis plays a critical role in the various forms of proteinuria. There was negative 
correlation between the levels of proteinuria and Dynamin in the serum; however the 
correlation was not significant statistically. 
Conclusion 
Cathepsin L could potentially serve as a biomarker of proteinuric kidney disease.  
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Preface 
Kidney disease is still a major problem in South Africa and worldwide. Early detection can 
aid in optimal management and hence delay requirement of renal replacement therapy and 
prevention of premature death. 
Understanding the pathobiology of the kidney can assist in discovery of biomarkers for 
proteinuric kidney disease. 
This research report is a prospective of 37 patients with proteinuric kidney disease versus a 
control group of 40 individuals where serum and urine levels of Dynamin and Cathepsin L 
levels will be compared between the two groups.   
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Chapter 1- Introduction and literature review 
1.1 Background 
Chronic kidney disease (CKD) has a significant impact on morbidity, mortality and high 
medical expenditure in South Africa and globally. It is therefore essential to detect it early in 
order to institute optimal management and prevent premature death. This will aid in 
preventing or delaying the requirement for renal replacement therapy. CKD may be present in 
more than 10% of the adult population in high risk groups. [Nicholas et al. 2005]. Risk 
factors include socio-demographic, genetic predisposition or the presence of diseases which 
can initiate and propagate kidney disease. [Nicholas et al. 2005]. In South African adults, 
hypertension (60-65%) or type 2 diabetes (another 20-25%) are the most common aetiologies 
of kidney failure [NATIONAL KIDNEY FOUNDATION SOUTH AFRICA].  The increased 
incidence of hypertension in the South African black population has led to kidney failure 
being four times more frequent than in other ethnic groups [NATIONAL KIDNEY 
FOUNDATION SOUTH AFRICA]. Glomerulonephritis was responsible for end-stage renal 
failure (ESRD) in 52.1% of hypertension and in 45.6% of patients on dialysis in South Africa 
[Naicker 2003].  It is recognized that the secondary pathological pathway leading to ESRD is 
a common pathway to all CKD and may inevitably progress to ESRD due to the repeated 
cycle of nephron destruction by progressive glomerulosclerosis and tubulointerstitial fibrosis 
[Zandi –Nejad et al. 2004].  
 
The National Kidney Foundation - Kidney Disease Outcomes Quality Initiative (NKF-
K/DOQI)  defines CKD as : “The presence of markers of kidney damage for ≥3 months, as 
defined by structural or functional abnormalities of the kidney with or without decreased 
glomerular filtration rate (GFR), that can lead to decreased GFR, manifest by either 
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pathological abnormalities or other markers of kidney damage, including abnormalities in 
the composition of blood or urine, or abnormalities in imaging tests OR The presence of GFR 
<60 mL/min/1.73 m2 for ≥3 months, with or without other signs of kidney damage as 
described above” [Koppel et al. 2011]. 
 
1.2 Proteinuria 
Proteinuria is the presence of an excess of proteins in the urine. Several hundred million 
people worldwide, including South Africa, are affected by proteinuria.  It serves as a 
prognostic indicator and sign of kidney disease and is the second most important parameter in 
the clinical evaluation of kidney function [Madias 2009].  In healthy individuals not more 
than 150 mg/day protein is excreted and consists predominantly of filtered plasma proteins 
and tubular Tamm-Horsfall proteins. Therefore, excretion of more than 150mg of protein is 
pathological and indicates increased permeability of the glomerular basement [Mundel 2010].  
There are various forms and different levels of severity for proteinuria. Types of proteinuria 
include the following: (i) Transient proteinuria, characterised by normal renal function, with 
no significant underlying renal disease. The proteinuria disappears upon repeat testing. (ii) 
Orthostatic proteinuria more common in tall, thin adolescents including younger adults of 
less than 30 years where renal function is normal and proteinuria is said to be less than 
1g/day. (iii) Persistent proteinuria: where albumin excretion is usually less than 500 mg/day; 
not indicative of progressive underlying renal disease, while persistent proteinuria more than 
500mg/day, is more likely to be due to glomerular disease [Springberg et al. 1982]. 
 Proteinuria does not merely reflect glomerular injury; it is also harmful. Intracellular signals 
are activated by increased glomerular permeability to proteins. This includes endothelin (ET-
1 vasoactive mediator), growth factors and inflammatory mediators. In the interstitium, these 
3 
 
substances will lead to recruitment of local inflammatory cells. In addition, there will be a 
release of cytokines/chemokines and growth factors and the production of extracellular 
matrix collagen and fibronectin that are responsible for interstitial fibrosis [Benigni 2009]. 
According to this, proteinuria is both a biomarker of kidney injury and a mediator of 
progressive kidney injury. 
 
1.3 Podocytes 
The kidney filters metabolic waste but, the passage of larger molecules e.g. albumin is 
prevented by filtration across the glomerular capillary wall [Gagliardini et al. 2010]. 
Therefore, defects in the glomerular capillary wall result in increased permeability to albumin 
and other plasma proteins causing proteinuria. The podocytes of the kidney and their foot 
processes function is to prevent urinary protein loss and maintain the ultrafiltration barrier 
[Gagliardini et al. 2010]. In proteinuria, podocyte membrane extensions reduce in number 
and size. The podocytes consist of foot process, major processes and a cell body, and they 
have a complex cellular organisation [Gagliardini et al. 2010]. To better appreciate the 
biology of glomerular podocytes, understanding the structural and functional anatomy of the 
glomerular capillary wall is important.  
 
The filtrate must pass through the glomerular capillary wall, which consists of three layers 
 (i) A fenestrated capillary endothelium-coated with a layer of polyanionic 
glycosaminoglycans and glycoproteins.(ii) A glomerular basement membrane (GBM), 
containing heparan sulphate and other anionic glycosaminoglycans and podocytes (or 
epithelial cells), which are attached to the GBM by discrete foot processes (FP). (iii)The slit 
diaphragm (SD) is a thin membrane that enclose the pores between the foot processes (slit 
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pores). Therefore SD functions as a modified adherens junction and may also be permeated 
by anatomical pores [Gagliardini et al. 2010]. 
 
Proteinuria results if there is any interference in any of the components of the glomerular 
capillary wall [Singh et al. 2007]. The adhesion molecules, such as alpha3beta1 integrin 
complex and dystroglycan (which are present on the basal membrane of foot processes), 
attach the podocyte to the GBM [Gagliardini et al. 2010].  Slit diaphragms join the 
interdigitating foot processes of adjacent podocytes and bridge the intervening filtration slits. 
The following proteins have been found to comprise the slit diaphragm [Tryggvason et al. 
2006]: Nephrin, Neph1 and Neph2, FAT1 and FAT 2, Podocin, Transient receptor potential 
cation channel 6 (TRPC6), Tight junction proteins, including junctional adhesion molecule A, 
occludin and cingulin [Fukasawa et al. 2009]. 
Mutations of some of the genes encoding slit diaphragm proteins causes rearrangement of the 
actin cytoskeleton and this results in foot process effacement, hence proteinuria [Jones et al. 
2009]. (Fig 1) below shows the architecture of normal podocytes and compares this to that 
where effacement has occurred leading to proteinuria 
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Fig1: a) Architecture of normal podocytes b) Podocytes in nephrotic syndrome 
 GBM giving support to glomerulus capillary tuft. Capillary lumen (CL) and mesangial cells 
are embraced by glomerular endothelial cells (E). Podocyte foot process (FP) cover the outer 
aspect of GBM. Podocyte cell bodies (CB) and major processes (MT) floats in primary urine 
in the Bowman’s space (BS). The plasma ultra-filtrate passes through fenestrated glomerular 
capillary endothelium, the GBM, and the filtration slits between neighbouring podocyte foot 
process. AA afferent arteriole, DT distal tubule, EE efferent arteriole. SEM, scanning 
electron microscopy, TEM, transmission electron microscopy  
    b) Effacement of the podocytes FP lose their normal interdigitating pattern 
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Proteinuria: an enzymatic disease of the podocyte?   [Mundel and Reiser. 2010] 
Reprinted with permission from J Clin Invest.2007; 117(8):2095-2104.doi:10.1172/JCI32022 
 
Fig 2: Podocyte slit diaphragm and proteins involved in the slit diaphragm [Ronco 
2007]. 
The cytoskeleton and components of the podocytes are represented. Dynamin cleavage by 
Cathepsin L, interferes with the normal function of Dynamin and induces cytoskeleton 
reorganization, and foot process effacement leading to proteinuria. 
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Reprinted with permission Ronco et al. J Clin Invest.2007; 117(8):2079-
2082.doi:10.1172/JCI32966. 
 
In glomerular diseases, including membranous glomerulopathy, minimal change disease 
(MCD), focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy the podocytes 
can be injured. Characteristic changes are disruption of the actin cytoskeleton which results in 
FP effacement and slit diaphragm (SD) disruption. Fig 2 [Mundel et al. 2010].  
 
 
 
Fig 3: In healthy individuals there is no podocyte effacement and passage of 
macromolecules is prohibited. [Ronco P. 2007] 
The glomerular filtration barrier. (Left) Normal filtration barrier restricts the passage of 
macromolecules. (Right) Cleavage of Dynamin by Cathepsin L leads to podocyte effacement 
and hence passage of macromolecules.  
Reprinted with permission J Clin Invest.2007; 117(8):2079-2082.doi:10.1172/JCI32966. 
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Interference with any components of FP will lead to changes of the actin cytoskeleton to a 
dense network with FP effacement from the normal parallel contractile bundles structure. 
There are also changes in slit diaphragm function and structure. The interference of GBM or 
podocyte–GBM interaction or the dysfunction of podocyte actin cytoskeleton leads to 
modulation of the negatively charged podocytes surface and activation of Cathepsin L-
mediated proteolysis (Figs 2, 3 and 4). [Mundel 2010] 
 
 
Fig 4: Consequence of podocyte injury [Mundel and Reiser 2010] 
Glomerular injury by different glomerular disease can be reversible or irreversible. In 
irreversible glomerular injury there is cell death and disruption of podocyte cytoskeleton and 
leads to end stage renal disease (ESRD). FP, foot process. SD, slit diaphragm. 
Reprinted with permission from J Clin Invest.2007; 117(8):2095-104.doi:10.1172/JCI32022. 
1.4 Dynamin  
According to mouse genetic and cell biologic studies, many proteins control the plasticity of 
the podocyte actin cytoskeleton [Sever et al. 2007]. These proteins include Dynamin, which 
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is a substrate for Cathepsin L. Dynamins belong to a super family of GTP-binding proteins 
that are involved in a diversity of membrane trafficking based processes [McNiven 2000]. 
Dynamins function as mechano-chemical scaffolding that hydrolyse GTP to constrict and 
alter biological membranes and recruit many different signalling, cytoskeletal and membrane 
coat proteins [Praefcke et al. 2004]. Dynamins are also essential for the development of 
clathrin-coated vesicles at the plasma membrane during endocytosis. They are also essential 
for the control of actin dynamics in some cell types. In other studies, Dynamin was showed to 
have a role in mediating microtubule sliding [Reems 2008]. Dynamins are involved in a 
variety of cellular processes. This includes the development of organelles involved in cell 
motility, membrane vesiculation from the plasma membrane and trans–Golgi network (e.g. 
endocytosis and secretion) and also in cytokinesis [Reiser et al. 2010]. 
The first Dynamin protein was isolated in 1989. Three members of the Dynamin family have 
been described. Dynamin 1 (DNM1) is neuronal–specific isoform, Dynamin 2 (DNM2) is 
ubiquitously expressed, and Dynamin 3 (DNM3) localizes in testes, brain, and lungs. The 
proteins encoded by these genes share the same domain organization and an overall 80% 
homology but have distinct expression patterns [Ferguson et al. 2012]. 
1.5 Cathepsin L 
The name Cathepsin L alludes to its “catheptic activity” which means to boil down or digest, 
originate from the Greek word Kathépsein. Cathepsin L was initially discovered in the gastric 
juice during the 1920s. [Reiser et al. 2010]’’ It is a lysosomal cysteine protease/ enzyme that 
plays a major role in intracellular protein catabolism. Cathepsin L is potent in degrading 
collagen, laminin, elastin as well as alpha 1 protease inhibitor and other structural proteins 
of basement membranes” [Q1A94 Cathepsin L Elisa kit protocol]. Cathepsins are present in 
most organisms including all animals. There are several members of this family and are 
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characterised by their structure, function, mechanism, and which proteins they cleave. Low 
pH in lysosomes is essential for Cathepsins to become activated [Nicholas et al. 2005]. 
Cathepsin L mRNA is found mostly in the kidney glomeruli, and is therefore characterized as 
a glomerular-specific transcript [Sever 2007]. In the podocytes, the cytosolic Cathepsin L 
degrades the GTPase Dynamin and Synaptopodin; the actin-binding protein. This results in 
the disruption of actin cytoskeleton hence FP effacement and subsequent proteinuria [Sever 
2007]. Foot process effacement can be prevented by the protecting of the target proteins from 
Cathepsin L proteolysis or by inhibition of Cathepsin L activity (figure 5). 
 
 Dynamin mutants, which contain mutated Cathepsin L cleavage sites, are not prone to 
proteinuria and can arrest and also reverse podocyte foot process effacement. [Nicholas 
2005]. These observations propose that Dynamin is important in preserving the ultrafiltration 
barrier in glomeruli, possibly by modulation the actin cytoskeleton and by Cathepsin L 
"switching off" the active, GTP-bound form of Dynamin.  This suggests that Dynamin is a 
key for podocyte structure in healthy kidneys. In support of this concept, expression of 
dominant-negative Dynamin in mice podocytes caused severe proteinuria [Schell et al. 2012].   
Levels of Cathepsin-L were found to be increased in the micro-dissected glomeruli of the 
biopsy of a murine model of minimal change disease- characterised by reversible podocyte 
foot process effacement. However, this increase was to a lesser extent compared to that of 
patients with membranous nephropathy, diabetic nephropathy and focal segmental 
glomerulosclerosis. The expression of a Cathepsin-L-degraded Dynamin fragment causes 
foot process effacement and proteinuria, whereas the expression of Cathepsin-L-resistant 
Dynamin mutants decreases proteinuria [Sever 2007]. 
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Fig 5: Left: physiological normal podocyte. On the right: podocyte under stress with 
Cathepsin L cleaving its substrates Dynamin and Synaptopodin leading to effacement 
[Schell C et al. 2012].  
Printed with permission from authors: Nephrol Dial Transplant.2012 Sep; 27(9):3406-12.doi: 
10.1093/ndt/gfs273.Epub 2012 Jul 5. 
 
A better understanding of podocyte pathobiology may pave the way for developing a cure for 
kidney diseases. To date, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II 
(AngII) receptor blockers have been used as the most effective anti-proteinuric drugs. They 
are also beneficial in haemodynamic effects and they may be involved in inhibiting AngII-
induced actin cytoskeleton reorganization [Macconi 2006]. Further investigation is still 
required to determine whether this effect also involves Cathepsin L inhibition, or active 
GTPase Dynamin stabilization.  Use of Dynamin mutants and Cathepsin L inhibitors seems 
to be on the horizon for management of proteinuric diseases, however, further investigation 
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must be explored. Literature further shows that cysteine protease inhibitors reduce proteinuria 
in rats possibly by inhibiting proteolysis of the glomerular basement membrane [Reiser 
2010]. Inhibition of cytosolic Cathepsin L and its substrate Dynamin, provide promising 
starting point for the development of selective, anti-proteinuric, and podocyte protective 
drugs. 
 
Even though albuminuria and proteinuria are used for non-invasive assessment of kidney 
diseases, they are however non-specific [Fukuda et al. 2011]. As mentioned above, evidence 
strongly suggests podocyte depletion from glomeruli results to glomerulosclerosis. Podocytes 
and their products can be detected in urine [Fukuda et al. 2011]. This potentially can be a 
non-invasive method to monitor the well-being of the podocytes. It suggests the prospect that 
biological markers of podocyte stress, disorganisation, or loss could be used together with 
proteinuria to more reliably monitor and detect progression and response to treatment.  
 
While measures of kidney function are still used to observe kidney diseases they are however 
insensitive as the kidney has considerable reserve function such that more than 50 % of 
nephrons have to become non-functional before kidney function becomes measurably 
abnormal [Fukuda et al. 2011]. The screening strategy that relies on functional measurements 
will, therefore, be insensitive and will tend to identify late stage disease. Podocyte injury and 
depletion are hence a driver for most forms of glomerular disease.  Therefore, this might 
indicate that podocytes and their products could be utilised as biomarkers of proteinuric 
kidney disease. Cathepsin L seems to be a promising biomarker in diagnosing of renal 
dysfunction [Huang et al. 2012]. Hence, the objective of my study is to determine the role of 
Dynamin and Cathepsin L as potential biomarkers of proteinuric kidney disease.  
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1.6 Hypothesis  
Serum and urine levels of Dynamin and Cathepsin L are increased in patients with proteinuric 
kidney disease compared to those without proteinuria. 
1.6 Objectives 
1. To determine the serum and urine levels of Cathepsin L and Dynamin in patients with 
proteinuric renal disease and normal cohorts using enzyme linked immunosorbent 
assays (ELISA) 
2.  To compare the levels of Cathepsin L and Dynamin in patients with proteinuric renal 
disease to those of normal controls. 
3. To determine if the level of Cathepsin L and Dynamin correlates with degree of 
proteinuria.  
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Chapter 2-Material and methods  
2.1 Ethics 
Informed consent was obtained from all the participants. This study was approved by the 
University of the Witwatersrand Human Research Ethics Committee (Medical). Ethics 
clearance number M120967. 
2.2 Sample collection and preparation 
Human samples: 77 participants were recruited and divided into two groups.  The first group 
comprised patients attending the Renal Clinic at Charlotte Maxeke Johannesburg Academic 
Hospital. This group was made up of patients known with proteinuric renal disease, mostly 
focal segmental glomerular sclerosis (FSGS) and HIV associated nephropathy (HIVAN). The 
second group was of 40 normal healthy controls with no background medical history, no 
proteinuria on dipsticks, and normal urinalysis with normal blood pressures. 
 Exclusion criteria 
• Patients with diabetes mellitus 
• Patients with malignancy 
• Age<18 >60 years 
• Patients with systemic lupus erythematosis or rheumatoid arthritis 
Blood and urine samples were collected from each participant. Urine samples were spun at 
1000xg for 20 minutes to remove particulate matter and aliquots stored at -80C. For the 
serum preparation, blood was collected and allowed to clot for 30 minutes before being 
centrifuged for 10 minutes at 1000xg. The serum was removed and aliquoted into cryotubes 
for storage at -80C.  
 
15 
 
2.3 Cathepsin L and Dynamin ELISA 
A Sandwich ELISA (enzyme linked immunosorbent assays) was used to determine the serum 
and urine levels of Cathepsin L and Dynamin and the procedures were carried out according 
to the manufacturer’s instructions (eBiosciences- and Cusabio Biotech Co Human Dynamin 2 
Elisa kit, respectively). The protocols are based on the same principle whereby the amount of 
antigen (Cathepsin L and Dynamin) is measured between two layers of antibodies namely, 
the capture and detection antibody. In this method, microtitre plates are coated with capture 
antibody. Following a blocking step, the urine and serum samples were added to each well in 
duplicate and following an incubation step, the plates were washed. A detection antibody was 
then added to each well. This antibody recognizes a second epitope of the target protein. 
After incubation and washing steps, a detection step was carried out. Both assays utilize the 
Horseradish peroxidase (HRP) enzyme for a colorimetric detection of signal. The substrate 
for HRP is hydrogen peroxide. Hydrogen peroxide cleavage is coupled to the oxidation of 
hydrogen donor which causes a colour change.  
The measurement of each signal was carried out using an ELISA plate reader (set at a 
primary wavelength of 450nm). The concentrations of Cathepsin L and Dynamin in each 
sample were interpolated from a standard curve prepared from readings obtained from 
duplicate sets of standards included in the assay.  
 
2.4 Data Analysis 
The sample size was determined from previous similar studies, with assistance of a 
statistician.  
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Sample size was calculated by comparing the means of the groups where the average value 
for sample 1= 1.0 (standard deviation=0.5); average value sample 2= 1.5 (standard 
deviation=0.5; alpha= 5% and beta= 20%A sample size of 20 was selected for the kidney 
disease group and 20 for the Control group (to give a 1:1 ratio). The numbers were there after 
doubled in order to improve the statistical significance. 
The levels of Cathepsin L and Dynamin were compared between the two groups using 
STATA 12.0 Wilcoxon non-parametric test. This was done due to the skewed distribution. 
This is an independent sample t-test to assess whether the mean Serum Dynamin, Urine 
Dynamin, Serum Cathepsin L and Urine Cathepsin L differs for the control group against the 
disease group. Pearson’s correlation analysis was used to measure the strength of the 
relationship between the variables. Statistical significance was considered as p-value <0.05. 
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Chapter 3-Results 
3.1 Demographic data 
Participants were divided into two groups: controls and those with proteinuria. 
 Control group- 40 health care workers and medical students with no apparent 
background medical history. 
 Normal urinalysis was present in all controls. 60% of the control group was females 
and 40% males. The age group ranged between 20 to 40 years. 
 Proteinuria group- comprised 37 patients attending the renal and HIV clinics with 
proteinuria on dipsticks and abnormal renal function (urea > 7.5 creatinine > 100 
mmol/L). 51% of proteinuric group were females and 49% males. 
 
3.2 Aetiology of chronic kidney disease 
HIV associated nephropathy (HIVAN) n=22 (59%) 
Focal segmental glomerulosclerosis (FSGS) n=10 (27%) 
 Membranoproliferative glomerulonephritis n=5 (14%) 
 
3.3 Levels of Cathepsin L and Dynamin in patients with proteinuric renal disease 
compared to normal control 
In the kidney disease group, the mean value for Cathepsin L in serum was 5.39±4.31 pg/ml 
while in the control group was 8.17±13.41 pg/ml showing no statistical significance. For 
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Dynamin the mean was 396.21±678.15 pg/ml for the kidney disease group while in the 
control group mean 206.66±174.24 pg/ml. The mean value of Cathepsin L in the urine of 
disease group was 10.44±11.47pg/ml while that of control group mean was 2.91±2.88 pg/ml 
with P-value of 0.000….hence statistically significant. The mean value for Dynamin in urine 
for the kidney disease group was 375.33±338.63pg/ml and for the control group 
523.41±492.49pg/ml. 
The results are shown in Table 1 below. 
Table 1: Comparison of the levels of Cathepsin L and Dynamin in patients with 
proteinuric renal disease to those of normal controls 
 
Kidney Disease (n=37) Controls (n=40) 
P-Value 
 
Mean 
(pg/ml) 
Standard 
Deviation 
(pg/ml) 
Mean 
(pg/ml) 
Standard 
Deviation 
(pg/ml) 
Dynamin (Serum) 396.2061 678.1511 206.6587 174.2392 0.107 
Dynamin (Urine) 375.3332 338.6343 523.4087 492.4917 0.131 
Cathepsin L (Serum) 5.3986 4.3180 8.1734 13.4144 0.233 
Cathepsin L( Urine) 10.4364 11.4709 2.9086 2.8773 0.000 
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Fig 6: Dynamin and Cathepsin L in serum and urine of disease vs. control group 
 
 
It is noted that there are no significant differences in the levels of Dynamin in serum and 
urine of patients with proteinuric renal disease and healthy controls (p-values 0.107 and 0.131 
respectively). 
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The spread of the analyte measurements are shown in the boxplots (Figs 7-10) below. 
 
 
Fig 7: Box plot showing the spread of Dynamin concentration (pg/ml) in serum of the 
kidney disease group vs the control group 
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Fig 8: Box plot showing spread of Dynamin levels (pg/ml) in the urine of kidney disease 
group vs the control group 
The results also revealed that there is no significant difference in the level of serum Cathepsin 
L between the kidney disease and the control groups, the p-value of the independent samples 
t-test was 0.233. 
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Fig 9: Box plot showing spread of Cathepsin L (pg/ml) in the serum of kidney disease vs 
control group 
The results showed that there is a significant increase in the level of urine Cathepsin L 
between the disease group (mean = 10.4364) and the control group (mean = 2.9086); p-
value= 0.000. The differences are illustrated graphically below; 
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Fig 10: Box plot showing spread of Cathepsin L levels (pg/ml) in the urine of the kidney 
disease vs control group 
3.4 Correlation between Cathepsin L and Dynamin with the degree of proteinuria 
Table 2: Correlation between Cathepsin L and Dynamin with the degree of proteinuria 
 
n 
Pearson 
Correlation with 
proteinuria 
P-value 
Cathepsin (Serum) 37 -0.222 0.186 
Cathepsin (Urine) 37 -0.070 0.682 
Dynamin (Serum) 37 0.116 0.493 
Dynamin (Urine) 37 -0.036 0.834 
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Although serum Cathepsin L (r = -0.222, p-value = 0.186), Urine Cathepsin L (r = -0.070, p-
value = 0.682), p-value = 0.665), and urine Dynamin (r = -0.036, p-value = 0.834) are 
negatively related to the degree of proteinuria, the correlation is not significant, all the p-
values were greater than 0.05; table 2. 
Serum Dynamin (r = 0.116, p-value = 0.493) had a positive correlation to the degree of 
proteinuria but the correlation was not significant at 5% significance level (the p-value was 
greater than 0.05). Thus, there is no correlation between Cathepsin L and Dynamin levels 
with the degree of proteinuria. 
 
3.5 Association between the level of proteinuria and patient’s gender 
 
Table 3: Comparison of the level of proteinuria between male and female patients 
 
Female (n=19) Male (n=18) 
P-
Value 
 
Mean Standard Deviation Mean Standard Deviation 
 
PCR(g/mmol) 0.9642 0.2443 0.4498 0.230 0.000 
PCR-protein creatinine ratio 
The results revealed that the level of proteinuria (as measured by urine PCR) is significantly 
higher among female patients (mean value = 0.9642) compared to a mean of 0.4498 among 
male patients; table 3. The means are significantly different since the p-value of the 
independent samples t-test was 0.000. The differences are also shown graphically in the box 
plot below (fig 11); 
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Fig 11: Box plot comparing proteinuria (g/mmol) in females vs. males 
 
It can be clearly seen that the levels of proteinuria is much higher among female patients. 
This, however is not in keeping with literature which postulates that the same reason that men 
are at risk for cardiovascular disease, also predispose them to risk of renal disease. However, 
our results could be due to sampling strategy. 
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Chapter 4-Discussion 
The aim of this study was to determine whether Cathepsin L and Dynamin could be used as 
biomarkers of proteinuric renal disease. We also wished to determine if the levels of 
Cathepsin L and Dynamin correlated with the degree of proteinuria. Dynamin and Cathepsin 
L have been proposed to be promising biomarkers for proteinuric kidney disease [Sever, 
2007]. Some biomarkers have been reviewed and have shown promising results but further 
validation is required. Literature shows podocyte loss as a key determinant of the progression 
of CKD and this is attributed to one of their specialised proteins, Dynamin – mechano-
chemical scaffolding that can hydrolyze GTP to constrict and deform biological membranes 
and recruit many different signaling, cytoskeletal and membrane coat proteins [Praefcke et al, 
2004]. Cathepsin L is responsible for podocyte foot process effacement by cleaving Dynamin 
in the cytoplasm. This results in reorganization of the podocyte actin cytoskeleton and 
subsequent proteinuria; this does imply that Dynamin is essential for podocyte morphology in 
healthy kidneys. 
 
The key finding in our study was that levels of Cathepsin L were elevated in the urine of the 
proteinuric group compared to the control group( p-value =0.00).This finding is similar to 
that of Sever, which showed that hydrolysis of Dynamin by a cytoplasmic  Cathepsin L leads 
to kidney podocyte effacement and  subsequently, proteinuria in the mouse models.  
Increased levels of glomerular Cathepsin L mRNA in microdissected glomeruli in some 
human proteinuric diseases were observed [Sever, 2007]. In another study, using the 
Cathepsin L inhibitor E-64, in a rat glomerulonephritis model, there was a reduction of 
proteinuria. This was attributed to inhibition of secreted Cathepsin L during matrix 
remodelling [Mundel, 2010].  The clinical relevance of this report is that Cathepsin L 
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expression is increased in proteinuric kidney disease. This, also, supports the concept that 
Cathepsin L plays an essential role in the occurrence of different forms of proteinuria [Reiser, 
2010]. In other studies, Cathepsin S was found in the proximal tubular cells and podocytes of 
proteinuric failing kidneys [Huang, 2012]. Cathepsin B and L activity was found to be 
decreased in the tubular cells of the kidneys from patients with early stage diabetic and 
hypertensive nephropathy [Huang, 2012], suggesting that the role of Cathepsins in various 
kidney diseases may differ among the various Cathepsin isoforms and stages of CKD 
[Huang, 2012].  
 
While the spectrum of function for Cathepsin L is very broad, two of its substrates Dynamin 
and Synaptopodin have been delineated in podocytes [Mundel, 2010]. They are both essential 
for the functional F-actin structure in normal podocyte FPs. Enzymatic processing of these 
substrates by Cathepsin L will lead to FP effacement [Mundel, 2010]. Chandel et al. 2013 
reported that podocyte Cathepsin L expression diminished Dynamin expression. Therefore, 
one can hypothesise that lack of Cathepsin L would increase podocyte Dynamin expression. 
Also, genetic and histological studies have shown that Dynamin reduction was Cathepsin L-
dependant, suggesting that the cytoplasmic Cathepsin L targets Dynamin [Sever, 2007]. 
However, the results of our study did not show any significant decrease in the levels of 
Dynamin in the proteinuric group compared with the control group. 
 
With Dynamin being Cathepsin L-dependant, we expected levels of Dynamin to be reduced 
in the proteinuric group. However this was not observed and whether this was due to the fact 
that Dynamin is ubiquitously expressed requires further studies. Cytoplasmic Cathepsin L 
seems to be specific, and its substrate is GTP-bound Dynamin. This implies that only a 
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portion of Dynamin can be hydrolysed in vivo [Sever, 2007]. Sever further showed that 
“Cathepsin L reduced endogenous Dynamin by only 30%, possibly maintaining Dynamins 
role in endocytosis.” In another study Soda et al., argued that Dynamin complete destruction 
is not necessarily required for kidney failure.  
 
Dynamin levels were expected to be higher in the control group than the proteinuric group; as 
stated earlier, Dynamin plays a vital role in the scaffolding of the podocyte slit diaphragm. 
Similarly, Cathepsin L levels were expected to be elevated in the proteinuric group. As has 
been postulated in the literature, Cathepsin L has a role in the development of proteinuria. In 
support of this, further studies suggested that the antiproteinuric activity of cyclosporine A 
results from direct protection of the podocyte cytoskeleton from Cathepsin L mediated 
proteolysis [Soda, 2012]. This explains how Cyclosporine A induces remission of proteinuria 
in some proteinuric diseases. In our study, the significant finding was elevated Cathepsin L 
levels in the urine of the proteinuric group. However, there was no significant increase in the 
serum levels of Cathepsin L, suggesting the possibility of a local paracrine effect of 
Cathepsin L in the kidney.  
 
In our data, too many outliers were observed in both the control group and kidney disease 
group (Figs.7-10). This may have impacted on our results, resulting in lack of statistical 
significance; we therefore suggest an optimal screening of the control group. In a study by 
Bauer et al., Cathepsin L was revealed as a potential sex-specific biomarker. Using rat 
models, they reported urinary Cathepsin L to be more elevated in male rats with proteinuria 
compared to females. Our study showed a similar trend; however it was not statistically 
significant. However, from our data, males were not exactly matched to females in terms of 
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numbers. Interestingly there were more females (51%) than males, yet Cathepsin L was 
found to be elevated in males.  Further studies are needed to confirm whether Cathepsin L 
can be used as a gender specific biomarker. In one study by Verhagen et al., they proposed 
that men were at greater risk for renal injury as oestrogens had protective effects and 
androgens predisposed to proteinuria. The exact mechanism is unknown, however the 
vasodilatory effects of oestrogens were postulated [Verhagen and Marjan 2000]. 
 
If Cathepsin L is implicated in proteinuric kidney disease, one may expect a correlation 
between the levels of Cathepsin L and the amount of proteinuria; however, this was not the 
case in our study. There was no correlation between either Cathepsin L or Dynamin with the 
degree of proteinuria. For many years, proteinuria has been used as a diagnostic and 
monitoring tool for kidney diseases. But, as mentioned earlier, it relies on the functional 
properties of the kidneys, and hence becomes abnormal at a very late stage. It is therefore not 
a very specific biomarker as it has to be interpreted in the context of the patient's body 
habitus as it relies on muscle mass, neurologic conditions and the clinical picture as a whole 
[Fukuda 2011]. Proteinuria remains a valuable tool for monitoring kidney injury and the 
response to treatment within a disease spectrum. Podocyte loss is a key determinant of the 
progression of kidney disease [Fukuda 2011].This raises the possibility that measuring 
podocyte products in urine could be a powerful tool to aid clinical decision-making, 
analogous to troponin in cardiac injury [Fukuda 2011]. Podocyte products in urine (including 
podocyte-specific proteins or mRNAs carried by cells, exosomes, or urosomes) in 
combination with proteinuria could provide additional information that would improve 
clinical decision-making [Fukuda 2011]. 
 
30 
 
 
Limitations 
The patients in the two groups were not ideally matched. Therefore with further studies, ideal 
matching of patients e.g. age groups and ethnicity is recommended. 
Screening of the control group was also not ideal. With further studies, the control group 
should be fully screened; e.g. the control group could be living renal transplant donors who 
have been shown to have normal renal function prior to uninephrectomy. 
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 Chapter 5 - Conclusion  
With CKD, being a significant health problem due to its morbidity and mortality, it has 
become quite clear that we need better biomarkers that can identify the problem early in 
disease progression. Different studies have shown that serum creatinine, GFR, and 
proteinuria are insensitive as they reflect late functional changes, and not early structural 
alterations in the kidney that would identify subtle damage. Therefore reliance on these may 
result in an extensive time lapse where successful interventions could be applied. 
 
In our study we showed increased levels of Cathepsin L in the urine of participants with 
proteinuric kidney disease compared to the control group. This is in agreement with earlier 
studies done, which showed that Dynamin reduction was Cathepsin L- dependent suggesting 
that cytoplasmic Cathepsin L targets Dynamin.This raises the possibility that the presence, or 
level of podocyte products in the urine and serum could be  useful as a biomarker for CKD. 
Hence Cathepsin L is a possible biomarker for proteinuric kidney disease. However, further 
review and deeper understanding is still needed as both histologic and genetic studies 
implicate podocytes as targets for CKD therapy. 
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Appendix 2 
 
 
INFORMATION LEAFLET AND INFORMED CONSENT 
STUDENT NUMBER: 0102409Y 
TITLE OF RESEARCH: CATHEPSIN L AND DYNAMIN- BIOMAKERS OF 
PROTEINURIC RENAL DISEASE? 
INVESTIGATOR:      Dr MPOTI SEBOKA 
   INTERNAL MEDICINE REGISTRAR 
   UNIVERSITY OF WITSWATERSRAND 
CONTACT DETAILS email mpseboka@yahoo.com 
   Cell 0828166508 
Hi, I am Dr Mpoti Seboka a registrar in the department of internal medicine.  I am currently 
doing a research for my MMED (Masters of Medicine). In this research I will be measuring 
enzymes Cathepsin L and Dynamin in urine samples and from blood serum, comparing their 
levels in patients with kidney disease and those without kidney disease (controls). 
Kidney disease is a worldwide problem and very expensive to treat. A sign of kidney disease 
is passing protein in urine due to damaged kidney cells. Recent studies suggest that Cathepsin 
L and Dynamin are involved in the process of losing protein in urine. Hence these enzymes 
can be target for medication that treats the protein loss, and can help in reducing this 
worldwide problem. 
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You are invited to consider taking part in this research study. Your participation is entirely 
voluntary. If you agree to participate in the study, I will first ask you questions concerning 
your health, such as whether you have any diseases like hypertension, diabetes or whether 
you are on any other treatment. If you agree, a medical examination will be done on you and 
your medical records reviewed. Volunteers with no medical records, about 5mls of blood will 
be taken from their forearms, this can inflict minimal discomfort or pain and there is minimal 
risk of bleeding from the side. You will also be asked to give a urine sample which will be 
examined for proteins and for the enzymes Cathepsin L and Dynamin. Refusal to participate 
will involve no penalty or lose of benefits which you are otherwise entitled to. 
Your participation in this study will contribute to medical knowledge that may help patients 
who have chronic kidney disease. You will not be paid to participate in this study. Funds will 
be sought for payment of all study procedures and expenses that you may incur as a direct 
result of this study. 
The clinical study protocol will be submitted to the University of Witwatersrand Human 
Research Ethics Committee for approval. If at any point require information regarding your 
rights as a research participant you are free to contact the ethics committee. Please be 
informed you are free to ask me any questions for your clarification. 
Thanking you in advance for participating in this study. 
 
Dr Mpoti Seboka 
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Appendix 3 
Cathepsin L levels 
Micro well strips were washed with a wash buffer and not allowed to dry. 
100µl of sample diluent were added in duplicate to the blank wells and 50µl to the sample 
wells. 
50µl of each sample was added in duplicate to the sample wells and 50µl of Biotin-Conjugate 
was added to each well. 
Samples were covered with adhesive film and incubated at room temperature for 2 hours. 
Micro wells were then washed and 100µl of Streptavidin-HRP was added to each well 
including the blank wells. 
Micro wells were then covered with adhesive film and incubated at room temperature for 1 
hour. 
After washing 3 times 100µl of TMB substrate solution was added to each well and incubated 
at room temperature for 10 minutes. 
The stop solution added and absorbance of each micro well read at 450nm as primary 
wavelength. 
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Appendix 4 
                                           INFORMED CONSENT: 
 I hereby confirm that Dr Seboka has informed me about the nature, conduct, benefits 
and risks of this clinical study. 
 I have received, read and understood the participant information leaflet regarding the 
clinical study.  
 I am aware that the results of the study including personal demographics will be 
anonymously processed into a study report. 
 I am aware that at any stage without prejudice I may withdraw my consent to 
participate in the study. 
 I have had sufficient opportunity to ask questions and therefore declare that I am 
prepared to in the study. 
PARTICIPANT: 
 
Printed Name   Signature / Mark or Thumbprint  Date and Time 
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I, Dr Seboka herewith confirm that the above participant had been fully informed about the 
nature, conduct and risks of the above study. 
STUDY DOCTOR: 
Dr Mpoti Seboka 
Printed Name   Signature / Mark or Thumbprint  Date and Time 
 
WITNESS 1: 
 
Printed Name   Signature                             Date and Time 
WITNESS 2: 
 
Printed Name   Signature                             Date and Time 
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CATHESPIN L AND DYNAMIN - BIOMARKERS IN PROTEINURIC KIDNEY 
DISEASE? 
  
Study Number: 
Investigator:          Dr Mpoti Seboka 
Participant Number:     
Group:     
Enrolment Date:     
  Date Done Results 
Age     
Sex     
Race     
Blood Pressure     
Weight     
Height     
BMI     
      
HIV     
 
    
 
    
 
    
     
HBV     
HCV     
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TB     
other infection     
other illness     
      
Urea     
Creatinine     
Estimated GFR     
      
Proteinuria     
Protein: Creatinine 
Ratio     
      
 
    
 
    
     
ARV's     
ACEI     
ARB     
Steroids     
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Data Sheet for control and participants with proteinuric kidney disease. 
Sa+A1:
K68mpl
e 
Dynamin_
Serum 
pg/ml 
Dynamin_
Urine 
pg/ml 
Cathepsin
_Serumpg
/ml 
Cathepsin_
Urine pg/ml 
Group 
Sample 
type 
race gender age pcr 
Sample 
01 
15,54 440,96 6,79 7,71 1 Disease 
  
f 
    
Sample 
02 
20,94 47,62 7,34 5,82 1 Disease 
  
m 
  
0,84 
Sample 
03 
5,76 248,69 6,55 19,25 1 Disease 
  
m 
  
0,65 
Sample 
04 
60,20 152,75 6,98 5,69 1 Disease 
  
m 
  
0,43 
Sample 
05 
60,20 1129,26 7,34 6,31 1 Disease 
  
f 
  
1,26 
Sample 
06 
213,69 180,80 6,85 5,94 1 Disease 
  
f 
  
0,55 
Sample 
07 
27,79 88,39 8,02 10,46 1 Disease 
  
f 
  
1,09 
Sample 
08 
145,08 440,96 5,88 4,72 1 Disease 
  
m 
  
0,27 
Sample 
09 
668,99 384,97 5,39 16,38 1 Disease 
  
m 
  
0,25 
Sample 
10 
95,24 180,80 5,33 4,47 1 Disease 
  
m 
  
0,84 
Sample 
11 
1005,63 645,51 9,60 4,60 1 Disease 
  
m 
    
Sample 
12 
769,95 106,84 7,47 5,57 1 Disease 
  
f 
    
Sample 
13 
118,08 570,88 8,75 7,83 1 Disease 
  
f 
    
Sample 
14 
27,79 152,75 6,98 5,94 1 Disease 
  
m 
    
Sample 
15 
118,08 1250,51 6,85 5,76 1 Disease 
  
m 
    
Sample 
16 
769,95 72,54 21,69 5,08 1 Disease 
  
m 
    
Sample 
17 
1454,10 13,89 7,59 17,36 1 Disease 
  
f 
    
Sample 
18 
305,50 23,54 6,24 7,10 1 Disease 
  
m 
  
0,03 
Sample 
19 
2033,24 248,69 7,77 32,93 1 Disease 
  
f 
    
Sample 
20 
95,24 645,51 7,47 5,08 1 Disease 
  
f 
  
0,77 
Sample 
21 
361,60 502,81 5,94 4,66 2 Control 
  
f 
    
Sample 
22 
176,77 384,97 7,04 4,45 2 Control 
  
f 
    
Sample 
23 
578,37 1520,11 6,55 5,82 2 Control 
  
f 
    
Sample 
24 
305,50 128,20 14,85 4,78 2 Control 
  
m 
    
Sample 
25 
145,08 59,04 5,27 4,66 2 Control 
  
m 
    
Sample 
26 
118,08 384,97 7,16 4,78 2 Control 
  
f 
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Sample 
27 
769,95 152,75 6,37 5,02 2 Control 
  
m 
    
Sample 
28 
361,60 128,20 5,21 5,94 2 Control 
  
m 
    
Sample 
29 
425,34 334,50 5,39 7,83 2 Control 
  
f 
    
Sample 
30 
578,37 502,81 6,24 4,66 2 Control 
  
f 
    
Sample 
31 
213,69 128,20 7,71 5,39 2 Control 
  
m 
    
Sample 
32 
668,99 180,80 4,84 4,72 2 Control 
  
f 
    
Sample 
33 
95,24 645,51 4,60 5,02 2 Control 
  
f 
    
Sample 
34 
47,07 289,18 6,24 5,51 2 Control 
  
m 
    
Sample 
35 
118,08 180,80 8,50 4,72 2 Control 
  
f 
    
Sample 
36 
27,79 289,18 5,14 5,82 2 Control 
  
f 
    
Sample 
37 
76,09 440,96 5,45 5,45 2 Control 
  
f 
    
Sample 
38 
27,79 570,88 5,33 5,27 2 Control 
  
f 
    
Sample 
39 
118,08 645,51 5,33 6,31 2 Control 
  
f 
    
Sample 
40 
76,09 727,05 6,61 5,39 2 Control 
  
f 
    
Sample 
41 
140,07 791,05 0,00 0,00 2 Control 
  
m 
    
Sample 
42 
91,94 164,15 0,00 0,00 2 Control 
  
m 
    
Sample 
43 
117,64 1747,98 7,52 0,00 2 Control 
  
f 
    
Sample 
44 
181,81 388,51 65,19 0,00 2 Control 
  
f 
    
Sample 
45 
153,56 471,20 0,00 9,22 2 Control 
  
m 
    
Sample 
46 
117,09 213,33 0,00 0,00 2 Control 
  
f 
    
Sample 
47 
123,78 892,18 6,39 0,96 2 Control 
  
m 
    
Sample 
48 
51,67 565,38 3,07 0,00 2 Control 
  
f 
    
Sample 
49 
188,75 114,86 7,25 0,00 2 Control 
  
f 
    
Sample 
50 
146,74 798,06 5,61 0,00 2 Control 
  
m 
    
Sample 
51 
265,39 537,76 6,83 0,00 2 Control 
  
f 
    
Sample 
52 
184,57 109,33 0,00 0,00 2 Control 
  
m 
    
Sample 
53 
152,31 71,44 0,00 0,00 2 Control 
  
m 
    
Sample 
54 
147,97 36,31 17,16 0,00 2 Control 
  
f 
    
Sample 
55 
143,08 1657,62 11,04 0,00 2 Control 
  
f 
    
Sample 85,56 867,89 0,00 0,00 2 Control   m     
45 
 
56 
Sample 
57 
190,16 15,35 5,27 0,00 2 Control 
  
m 
    
Sample 
58 
167,69 1378,66 0,00 0,00 2 Control 
  
f 
    
Sample 
59 
148,59 1842,36 61,84 0,00 2 Control 
  
f 
    
Sample 
60 
178,39 76,49 0,00 0,00 2 Control 
  
m 
    
Sample 
61 
88,48 223,91 0,00 0,00 1 Disease 
  
m 
  
0,37 
Sample 
62 
212,76 16,13 0,00 9,90 1 Disease 
  
f 
  
1,12 
Sample 
63 
52,90 77,17 10,93 9,96 1 Disease 
  
f 
  
0,63 
Sample 
64 
0,20 323,20 0,00 23,13 1 Disease 
  
m 
  
0,38 
Sample 
65 
275,96 582,15 0,00 0,00 1 Disease 
  
f 
  
1,14 
Sample 
66 
245,90 1078,95 0,00 7,08 1 Disease 
  
m 
  
0,49 
Sample 
67 
201,63 446,58 5,10 9,66 1 Disease 
  
f 
  
0,71 
Sample 
68 
101,07 328,97 1,17 0,00 1 Disease 
  
f 
  
0,58 
Sample 
69 
122,09 348,62 3,54 3,59 1 Disease 
  
f 
  
1,39 
Sample 
70 
516,09 478,52 0,00 51,01 1 Disease 
  
m 
  
0,4 
Sample 
71 
85,56 453,47 6,69 37,42 1 Disease 
  
m 
  
0,63 
Sample 
72 
126,05 74,12 5,10 32,42 1 Disease 
  
f 
  
0,84 
Sample 
73 
139,48 46,23 0,00 2,59 1 Disease 
  
f 
  
1,24 
Sample 
74 
116,54 273,90 0,00 0,00 1 Disease 
  
f 
  
0,84 
Sample 
75 
3504,21 161,26 0,00 12,11 1 Disease 
  
f 
  
1,04 
Sample 
76 
316,30 911,74 7,79 0,00 1 Disease 
  
m 
  
0,56 
Sample 
77 
543,41 1036,55 2,55 3,28 1 Disease 
  
M 
  
0,44 
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Theresa Kaiser  
 
Sep 14 (3 days ago) 
   
 to me  
 
 
Dr. Seboka,  
 
For use in your research project, please accept this email as permission granted to 
use Figures in the article by Dr. Ronco.  Please be sure to cite to the JCI as the 
original source.  Proper citation is as follows: 
Proteinuria: is it all in the foot? 
 
Pierre Ronco 
Published August 1, 2007  
Citation Information: J Clin Invest. 2007; 117(8):2079-2082. doi: 10.1172/JCI32966. 
 
 
Sincerely, 
Theresa Kaiser 
 
 
If you have any questions, please feel free to contact us. 
 
Sincerely,  
Theresa Kaiser 
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Prof. Dr. Tobias Huber  
 
Sep 12 (5 days ago) 
   
 to me  
 
 
Sure, no problem. 
However, you should cite the source. 
Best, 
tobias 
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Theresa Kaiser <staff@the-jci.org>  
 
Jun 8 
   
 to me  
 
 
Hi Dr. Seboka,  
 
You may use the Figures for your mmed.  Please cite to the JCI as the original 
source of the figures, as follows: 
Proteolytic processing of Dynamin by cytoplasmic Cathepsin L is a mechanism for proteinuric kidney disease 
 
Sanja Sever ... Boris Nikolic, Jochen Reiser 
Published August 1, 2007  
Citation Information: J Clin Invest. 2007; 117(8):2095-2104. Doi: 10.1172/JCI32022. 
 
 
 
 
 
 
 
 
If you have any questions, please feel free to contact us. 
 
Sincerely, 
Theresa Kaiser 
 
